The immunological challenges of malaria vaccine development

• SCHOFIELD L, HACKETT F: Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites. J. Exp. Med. (1993) 177(1):145-153.
   PubMed Web of Science ®Google Scholar
• NAIK RS, BRANCH OH, WOODS AS et al.: Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. J. Exp. Med. (2000) 192(11):1563-1576.
   PubMed Web of Science ®Google Scholar
• MILLER LH, BARUCH DI, MARSH K, DOUMBO OK: The pathogenic basis of malaria. Nature (2002) 415(6872):673-679.
   PubMed Web of Science ®Google Scholar
• SCHELLENBERG D, ABDULLA S, ROPER C: Current issues for anti-malarial drugs to control P. falciparum malaria. Curr. Mol. Med. (2006) 6(2):253-260.
   PubMed Web of Science ®Google Scholar
• MIKOLAJCZAK SA, ALY AS, KAPPE SH: Preerythrocytic malaria vaccine development. Curr. Opin. Infect. Dis. (2007) 20(5):461-466.
   PubMed Web of Science ®Google Scholar
• CHEN Q: The naturally acquired immunity in severe malaria and its implication for a PfEMP-1 based vaccine. Microbes Infect. (2007) 9(6):777-783.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JE, GIERSING B, MULLEN G, MOORTHY V, RICHIE TL: Malaria vaccines: are we getting closer? Curr. Opin. Mol. Ther. (2007) 9(1):12-24.
   PubMed Web of Science ®Google Scholar
• SAUERWEIN RW: Malaria transmission-blocking vaccines: the bonus of effective malaria control. Microbes Infect. (2007) 9(6):792-795.
   PubMed Web of Science ®Google Scholar
• SNOUNOU G, RENIA L: The vaccine is dead – long live the vaccine. Trends Parasitol. (2007) 23(4):129-132.
   PubMed Web of Science ®Google Scholar
• SCHOFIELD L, GRAU GE: Immunological processes in malaria pathogenesis. Nat. Rev. Immunol. (2005) 5(9):722-735.
   PubMed Web of Science ®Google Scholar
• SCHOFIELD L, HEWITT MC, EVANS K, SIOMOS MA, SEEBERGER PH: Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature (2002) 418(6899):785-789.
   PubMed Web of Science ®Google Scholar
• GUPTA S, SNOW RW, DONNELLY CA, MARSH K, NEWBOLD C: Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat. Med. (1999) 5(3):340-343.
   PubMed Web of Science ®Google Scholar
• BAIRD JK, JONES TR, DANUDIRGO EW et al.: Age-dependent acquired protection against Plasmodium falciparum in people having two years exposure to hyperendemic malaria. Am. J. Trop. Med. Hyg. (1991) 45(1):65-76.
   PubMed Web of Science ®Google Scholar
• BAIRD JK, PURNOMO, BASRI H et al.: Age-specific prevalence of Plasmodium falciparum among six populations with limited histories of exposure to endemic malaria. Am. J. Trop. Med. Hyg. (1993) 49(6):707-719.
   PubMed Web of Science ®Google Scholar
• REYBURN H, MBATIA R, DRAKELEY C et al.: Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria. JAMA (2005) 293(12):1461-1470.
   PubMed Web of Science ®Google Scholar
• BULL PC, MARSH K: The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol. (2002) 10(2):55-58.
   PubMed Web of Science ®Google Scholar
• ADKINS B, LECLERC C, MARSHALL-CLARKE S: Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. (2004) 4(7):553-564.
   PubMed Web of Science ®Google Scholar
• MUTHUKKUMAR S, GOLDSTEIN J, STEIN KE: The ability of B cells and dendritic cells to present antigen increases during ontogeny. J. Immunol. (2000) 165(9):4803-4813.
   PubMed Web of Science ®Google Scholar
• TONGREN JE, DRAKELEY CJ, MCDONALD SL et al.: Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect. Immun. (2006) 74(1):257-264.
   PubMed Web of Science ®Google Scholar
• PICHYANGKUL S, YONGVANITCHIT K, KUM-ARB U et al.: Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a toll-like receptor 9-dependent pathway. J. Immunol. (2004) 172(8):4926-4933.
   PubMed Web of Science ®Google Scholar
• COBAN C, ISHII KJ, KAWAI T et al.: Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J. Exp. Med. (2005) 201(1):19-25.
   PubMed Web of Science ®Google Scholar
• PARROCHE P, LAUW FN, GOUTAGNY N et al.: Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc. Natl. Acad. Sci. USA (2007) 104(6):1919-1924.
   PubMed Web of Science ®Google Scholar
• KRISHNEGOWDA G, HAJJAR AM, ZHU J et al.: Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J. Biol. Chem. (2005) 280(9):8606-8616.
   PubMed Web of Science ®Google Scholar
• MUNIZ-JUNQUEIRA MI, DOS SANTOS-NETO LL, TOSTA CE: Influence of TNF-α on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro. Cell Immunol. (2001) 208(2):73-79.
   PubMed Web of Science ®Google Scholar
• BRUNA-ROMERO O, RODRIGUEZ A: Dendritic cells can initiate protective immune responses against malaria. Infect. Immun. (2001) 69(8):5173-5176.
   PubMed Web of Science ®Google Scholar
• VICHCHATHORN P, JENWITHISUK R, LEELAUDOMLIPI S et al.: Induction of specific immune responses against the Plasmodium vivax liver-stage via in vitro activation by dendritic cells. Parasitol. Int. (2006) 55(3):187-193.
   PubMed Web of Science ®Google Scholar
• PLEBANSKI M, HANNAN CM, BEHBOUDI S et al.: Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunol. Cell Biol. (2005) 83(3):307-312.
   PubMed Web of Science ®Google Scholar
• ING R, SEGURA M, THAWANI N, TAM M, STEVENSON MM: Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. J. Immunol. (2006) 176(1):441-450.
   PubMed Web of Science ®Google Scholar
• POUNIOTIS DS, PROUDFOOT O, BOGDANOSKA V et al.: Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect. Immun. (2004) 72(9):5331-5339.
   PubMed Web of Science ®Google Scholar
• STEPHENS R, ALBANO FR, QUIN S et al.: Malaria-specific transgenic CD4(+) T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody production for parasite clearance. Blood (2005) 106(5):1676-1684.
   PubMed Web of Science ®Google Scholar
• VON DER WEID T, HONARVAR N, LANGHORNE J: Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J. Immunol. (1996) 156(7):2510-2516.
   PubMed Web of Science ®Google Scholar
• LUTY AJ, PERKINS DJ, LELL B et al.: Low interleukin-12 activity in severe Plasmodium falciparum malaria. Infect. Immun. (2000) 68(7):3909-3915.
   PubMed Web of Science ®Google Scholar
• PERKINS DJ, WEINBERG JB, KREMSNER PG: Reduced interleukin-12 and transforming growth factor-β1 in severe childhood malaria: relationship of cytokine balance with disease severity. J. Infect. Dis. (2000) 182(3):988-992.
   PubMed Web of Science ®Google Scholar
• MALAGUARNERA L, IMBESI RM, PIGNATELLI S et al.: Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease. Parasite Immunol. (2002) 24(7):387-389.
   PubMed Web of Science ®Google Scholar
• TORRE D, SPERANZA F, GIOLA M et al.: Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clin. Diagn. Lab. Immunol. (2002) 9(2):348-351.
   PubMedGoogle Scholar
• RHEE MS, AKANMORI BD, WATERFALL M et al.: Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria. Clin. Exp. Immunol. (2001) 126(3):503-510.
   PubMed Web of Science ®Google Scholar
• WINKLER S, WILLHEIM M, BAIER K et al.: Reciprocal regulation of Th1- and Th2-cytokine-producing T cells during clearance of parasitemia in Plasmodium falciparum malaria. Infect. Immun. (1998) 66(12):6040-6044.
   PubMed Web of Science ®Google Scholar
• LUTY AJ, LELL B, SCHMIDT-OTT R et al.: Interferon-γ responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. (1999) 179(4):980-988.
   PubMed Web of Science ®Google Scholar
• WALTHER M, WOODRUFF J, EDELE F et al.: Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J. Immunol. (2006) 177(8):5736-5745.
   PubMed Web of Science ®Google Scholar
• HIRUNPETCHARAT C, FINKELMAN F, CLARK IA, GOOD MF: Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. Parasite Immunol. (1999) 21(6):319-329.
   PubMed Web of Science ®Google Scholar
• LI C, CORRALIZA I, LANGHORNE J: A defect in interleukin-10 leads to enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. Infect. Immun. (1999) 67(9):4435-4442.
   PubMed Web of Science ®Google Scholar
• YOSHIMOTO T, TAKAHAMA Y, WANG CR et al.: A pathogenic role of IL-12 in blood-stage murine malaria lethal strain Plasmodium berghei NK65 infection. J. Immunol. (1998) 160(11):5500-5505.
   PubMed Web of Science ®Google Scholar
• DODOO D, OMER FM, TODD J et al.: Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J. Infect. Dis. (2002) 185(7):971-979.
   PubMed Web of Science ®Google Scholar
• KWIATKOWSKI D, HILL AV, SAMBOU I et al.: TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet (1990) 336(8725):1201-1204.
   PubMed Web of Science ®Google Scholar
• KREMSNER PG, WINKLER S, BRANDTS C et al.: Prediction of accelerated cure in Plasmodium falciparum malaria by the elevated capacity of TNF production. Am. J. Trop. Med. Hyg. (1995) 53(5):532-538.
   PubMed Web of Science ®Google Scholar
• GRAU GE, TAYLOR TE, MOLYNEUX ME et al.: Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. (1989) 320(24):1586-1591.
   PubMed Web of Science ®Google Scholar
• BROWN H, TURNER G, ROGERSON S et al.: Cytokine expression in the brain in human cerebral malaria. J. Infect. Dis. (1999) 180(5):1742-1746.
   PubMed Web of Science ®Google Scholar
• OMER FM, DE SOUZA JB, RILEY EM: Differential induction of TGF-β regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J. Immunol. (2003) 171(10):5430-5436.
   PubMed Web of Science ®Google Scholar
• WALTHER M, TONGREN JE, ANDREWS L et al.: Upregulation of TGF-β, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 23(3):287-296.
   PubMed Web of Science ®Google Scholar
• NEWMAN KC, KORBEL DS, HAFALLA JC, RILEY EM: Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-γ responses to malaria. PLoS Pathog. (2006) 2(12):E118.
   PubMed Web of Science ®Google Scholar
• STOUTE JA, SLAOUI M, HEPPNER DG et al.: A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S malaria vaccine evaluation group. N. Engl. J. Med. (1997) 336(2):86-91.
   PubMed Web of Science ®Google Scholar
• BOJANG KA, MILLIGAN PJ, PINDER M et al.: Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: a randomised trial. Lancet (2001) 358(9297):1927-1934.
   PubMed Web of Science ®Google Scholar
• ALONSO PL, SACARLAL J, APONTE JJ et al.: Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 364(9443):1411-1420.
   PubMed Web of Science ®Google Scholar
• SMITH PG, MILLIGAN PJ: Malaria vaccine: 3 or 6 months' protection? Lancet (2005) 365(9458):472-473.
   PubMedGoogle Scholar
• VANDERBERG JP, FREVERT U: Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int. J. Parasitol. (2004) 34(9):991-996.
   PubMed Web of Science ®Google Scholar
• LALVANI A, MORIS P, VOSS G et al.: Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine. J. Infect. Dis. (1999) 180(5):1656-1664.
   PubMed Web of Science ®Google Scholar
• STOUTE JA, KESTER KE, KRZYCH U et al.: Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. (1998) 178(4):1139-1144.
   PubMed Web of Science ®Google Scholar
• SUN P, SCHWENK R, WHITE K et al.: Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol. (2003) 171(12):6961-6967.
   PubMed Web of Science ®Google Scholar
• WANG R, EPSTEIN J, CHAROENVIT Y et al.: Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol. (2004) 172(9):5561-5569.
   PubMed Web of Science ®Google Scholar
• DOOLAN DL, MARTINEZ-ALIER N: Immune response to pre-erythrocytic stages of malaria parasites. Curr. Mol. Med. (2006) 6(2):169-185.
   PubMed Web of Science ®Google Scholar
• ALONSO PL, SACARLAL J, APONTE JJ et al.: Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet (2005) 366(9502):2012-2018.
   PubMed Web of Science ®Google Scholar
• BEJON P, ANDREWS L, ANDERSEN RF et al.: Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J. Infect. Dis. (2005) 191(4):619-626.
   PubMed Web of Science ®Google Scholar
• SCHELLENBERG D, MENENDEZ C, APONTE JJ et al.: Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. Lancet (2005) 365(9469):1481-1483.
   PubMed Web of Science ®Google Scholar
• OTOO LN, RILEY EM, MENON A, BYASS P, GREENWOOD BM: Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis. Trans. R Soc. Trop. Med. Hyg. (1989) 83(6):778-782.
   PubMed Web of Science ®Google Scholar
• DIALLO DA, SUTHERLAND C, NEBIE I et al.: Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug-resistant parasites better than unprotected children. J. Infect. Dis. (2007) 196(1):138-144.
   PubMed Web of Science ®Google Scholar
• POMBO DJ, LAWRENCE G, HIRUNPETCHARAT C et al.: Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet (2002) 360(9333):610-617.
   Web of Science ®Google Scholar
• ELLIOTT SR, KUNS RD, GOOD MF: Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect. Immun. (2005) 73(4):2478-2485.
   PubMed Web of Science ®Google Scholar
• BELNOUE E, COSTA FT, FRANKENBERG T et al.: Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. (2004) 172(4):2487-2495.
   PubMed Web of Science ®Google Scholar
• MACETE E, APONTE JJ, GUINOVART C et al.: Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1 – 4 in Mozambique. Trop. Med. Int. Health (2007) 12(1):37-46.
   PubMed Web of Science ®Google Scholar
• ZAVALA F, TAM JP, HOLLINGDALE MR et al.: Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (1985) 228(4706):1436-1440.
   PubMed Web of Science ®Google Scholar
• HOFFMAN SL, OSTER CN, PLOWE CV et al.: Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 237(4815):639-642.
   PubMed Web of Science ®Google Scholar
• QUE JU, CRYZ SJ Jr, BALLOU R et al.: Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites. Infect. Immun. (1988) 56(10):2645-2649.
   PubMed Web of Science ®Google Scholar
• MOSER K, TOKOYODA K, RADBRUCH A, MACLENNAN I, MANZ RA: Stromal niches, plasma cell differentiation and survival. Curr. Opin. Immunol. (2006) 18(3):265-270.
   PubMed Web of Science ®Google Scholar
• MANZ RA, HAUSER AE, HIEPE F, RADBRUCH A: Maintenance of serum antibody levels. Annu. Rev. Immunol. (2005) 23:367-386.
   PubMed Web of Science ®Google Scholar
• CROTTY S, FELGNER P, DAVIES H et al.: Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. (2003) 171(10):4969-4973.
   PubMed Web of Science ®Google Scholar
• RADBRUCH A, MUEHLINGHAUS G, LUGER EO et al.: Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. (2006) 6(10):741-750.
   PubMed Web of Science ®Google Scholar
• STRUIK SS, RILEY EM: Does malaria suffer from lack of memory? Immunol. Rev. (2004) 201:268-290.
   PubMed Web of Science ®Google Scholar
• DRAKELEY CJ, CORRAN PH, COLEMAN PG et al.: Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc. Natl. Acad. Sci. USA (2005) 102(14):5108-5113.
   PubMed Web of Science ®Google Scholar

Websites

• http://www.malariavaccineroadmap.net/
   Google Scholar
• http://www.who.int/vaccine_research/documents/RainbowTable_ClinicalTrials_December2006.pdf WHO website release (December 2006).
   Google Scholar